Radiomic-signature changes after early treatment improve the prediction of progression-free survival in patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer
Donghui Hou(Chinese Academy of Medical Sciences & Peking Union Medical College), Shijun Zhao(Second Hospital of Shandong University), Zewei Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Wei Song(Xuzhou Medical College), Lv Lv(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaomin Zheng(Tsinghua University), Xiaoqing Liu(Fujian Medical University), Sicong Wang(Griffith University), Ning Wu(Regeneron (United States)), Qi Sun(First Affiliated Hospital of Xi'an Jiaotong University), Lieming Ding(Betta Pharmaceuticals (China)), Lina Zhou(Nanjing University of Chinese Medicine), Xiuli Tao(Chinese Academy of Medical Sciences & Peking Union Medical College), Yujing Jin(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 1
Related Papers
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
|Journal of Thoracic Oncology|2020|415
A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy
|Clinical Cancer Research|2018|198
Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations
|Cell Metabolism|2023|191
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
|The Lancet Respiratory Medicine|2021|183